Monte Rosa Therapeutics (GLUE) drew fresh attention after reporting strong interim Phase 1 results for MRT-8102, its NEK7-directed molecular glue degrader. The data showed rapid, sustained reductions ...

The official selections, made by the Football Coaches Association, for the CIF-SS teams and individual awards.

Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines ...

Monte Rosa Therapeutics (GLUE) announced a public offering of 11,125,000 shares of its common stock at $24.00 each. It will ...

Jefferies, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering. Wedbush PacGrow and LifeSci Capital are acting as passive bookrunners for the offering.

The Chinese Ski Association has selected the Oasi Zegna Ski Racing Center as its training base until Jan. 19 in preparation ...

As of Thursday, January 08, Monte Rosa Therapeutics, Inc.’s GLUE share price has surged by 8.03%, which has investors ...

Monte Rosa’s MRT-8102 Phase 1 shows deep NEK7 degradation and strong hsCRP drops; plus $200M raise extends runway. Learn more ...

Monte Rosa Therapeutics Inc. followed up December’s positive prostate cancer data with strong interim findings from a phase I ...

This article originally published at Major Bay Area highway reduced to 1 lane indefinitely after storm damage.

Jefferies, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering. Wedbush PacGrow and LifeSci Capital are acting as passive bookrunners for this offering.

Monte Rosa Therapeutics (GLUE) commenced an underwritten public offering of $200M of common stock and pre-funded warrants. All shares and warrants in the offering are being sold by the company.